-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
-
Swiss Reusser wins Tour de France Femmes time-trial
-
Arsenal step up bid to sign Newcastle's Guimaraes: reports
-
Hundreds flee homes after Guatemala's Fuego volcano erupts
-
Gazans hold mass funeral for those killed during war
-
Thousands pay tribute to Italian football legend Baresi
-
WHO pleads for more support to tackle Ebola outbreak
-
Oil drops, stocks hit records on hopes of Hormuz opening
-
Oil drops, stocks gain on hopes of Hormuz opening
-
Renard returns as Ivory Coast coach
-
Infantino faces nervy times to see if challenger emerges
-
Italian garbagemen help recover lost 1 mln euro lottery ticket
-
Greece gains ground against blaze near Athens
-
EU nations patch things up after Ceuta migration discord
-
Oil turns lower, stocks gain on hopes of Hormuz opening
-
US hopeful Hormuz strait deal will be done 'today or tomorrow' after ship hit
-
World Bank warns developing countries to embrace AI or be left behind
-
Infantino's problems mount as Wenger and key FIFA ally turn on him
-
'No decision' on Mudryk future after Chelsea return: Alonso
-
Oil edges higher, stocks gain as investors eye political risks
-
China draws up safety rules for autonomous vehicles
-
Man Utd sign reported record £20mn sponsorship deal for training kit
-
Wenger says scrapping Infantino's World Cup plan was "absolutely necessary"
-
Stokes reveals England coaching ambition
-
Spain confronts EU migration hawks in tense Ceuta talks
-
Cargo ship hit after Trump insists Iran talks could reopen Hormuz today
-
Firefighters hope to contain blaze on Athens outskirts
-
BP profit soars as Mideast war roils energy prices
-
Heatwave divides rich and poor of upmarket Seoul
-
Most stock markets gain, while oil prices edge up after plunge
-
Drone strike on Moscow region kills 5
-
Most stock markets gain, while oil prices edge up after latest plunge
-
Guatemala issues 'danger' alert after Fuego volcano erupts
-
Weak yen helps auto giant Toyota raise forecasts
-
Heat kills 16 in South Korea this summer: interior ministry
-
TRON DAO Joins Blockchain Application Stanford Summit at the Science of Blockchain Conference as a Sponsor
-
Arson suspect arrested as US northwest battles wildfires
-
Rockets, Starlink, AI: SpaceX faces its first Wall Street grilling
-
Britain's Royal Mint strikes gold in electronic waste
-
After sparring over Ceuta, EU states seek lessons from crisis
US court restricts access to abortion pill, ruling on hold
A US federal appeals court on Wednesday imposed restrictions on a widely used abortion pill, but the ruling will remain on hold as the Supreme Court decides whether to hear the case.
The ruling by a three-judge panel of the New Orleans-based 5th Circuit Court of Appeals would limit use of mifepristone to the first seven weeks of pregnancy, instead of 10, and block it from being distributed by mail.
It would also require the abortion pill, which accounts for more than half of the abortions in the United States, to be prescribed by a doctor.
Despite the ruling by the panel of conservative judges, two of whom were appointed by former president Donald Trump and one by former president George W. Bush, the drug will remain on the market for the time being.
Anti-abortion groups are seeking to have mifepristone banned, claiming despite its long track record that it is unsafe. The case is the latest skirmish in the battle over reproductive rights in the United States.
The appeals court said the Food and Drug Administration (FDA), which approved the abortion pill in 2000 and made it more readily available in 2016, "failed to address several important concerns about whether the drug would be safe for the women who use it."
At a hearing in May, the three judges pushed back against government arguments that the decision on whether to allow the use of mifepristone should be left to the FDA.
The case stems from a ruling by a conservative US District Court judge in Texas that would have banned mifepristone.
The 5th Circuit Court blocked a ban on the abortion pill, but imposed restrictions on access, after which the baton was handed to the Supreme Court, where conservatives wield a 6-3 majority.
The Supreme Court temporarily preserved access to mifepristone, freezing the rulings by the lower courts and sending the case back to the 5th Circuit, whose latest decision will also remain on hold until the nation's highest court decides whether it will hear the case.
It would be the most significant abortion case to reach the nine-member Supreme Court since it overturned the constitutional right to the procedure in June of last year.
Since then, some 20 states, mostly in the South and the Midwest, have prohibited abortion outright or restricted access while others, mainly on the coasts, have moved to protect it.
- 'Exemplary safety' -
Reacting to the 5th Circuit ruling, the Center for Reproductive Rights said there is "scientific CONSENSUS on the exemplary safety and efficacy of mifepristone.
"Medication abortion is used in over half of all abortions in the US and the imposition of outdated, unscientific restrictions will harm millions of the most vulnerable pregnant people in the US," it said.
Katie Daniel, state policy director of the anti-abortion group Susan B. Anthony Pro-Life America, welcomed the court's decision.
"The FDA ignored science and its own rules when it rubber-stamped Democrats' reckless mail-order abortion scheme," Daniel said.
"We won't rest until the FDA and the profit-driven abortion industry are held accountable for the suffering they've inflicted on women and girls, as well as the deaths of countless unborn children," she said.
The FDA estimates that 5.6 million Americans have used it to terminate pregnancies since mifepristone was approved in 2000.
Z.AlNajjar--SF-PST